Show simple item record

Post-vaccination SARS-cov-2 infection in nursing home residents, Bordeaux, France

dc.rights.licenseopenen_US
dc.contributor.authorLARTIGAU, Marion
dc.contributor.authorOUATTARA, Eric
hal.structure.identifierMicrobiologie Fondamentale et Pathogénicité [MFP]
dc.contributor.authorTUMIOTTO, Camille
hal.structure.identifierMicrobiologie Fondamentale et Pathogénicité [MFP]
hal.structure.identifierCHU Bordeaux
dc.contributor.authorWODRICH, Harald
dc.contributor.authorBUSSON, Laurent
dc.contributor.authorTRIMOULET, Pascale
hal.structure.identifierCHU Bordeaux
dc.contributor.authorTHIEL, Elise
dc.contributor.authorNOUZILLE, Mahissata
dc.contributor.authorDUBOS, Maria
hal.structure.identifierMicrobiologie Fondamentale et Pathogénicité [MFP]
dc.contributor.authorLAFON, Marie-Edith
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorGILLERON, Veronique
hal.structure.identifierBordeaux population health [BPH]
hal.structure.identifierCHU Bordeaux
dc.contributor.authorDEHAIL, Patrick
dc.contributor.authorSALLES, Nathalie
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMALVY, Denis
dc.date.accessioned2023-05-16T12:41:36Z
dc.date.available2023-05-16T12:41:36Z
dc.date.issued2022
dc.identifier.issn1386-6532en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/182158
dc.description.abstractEnOBJECTIVE: To describe COVID-19 breakthrough infections in two nursing homes (NHs) sites of active COVID-19 clusters despite optimal vaccination coverage.METHODS: A cross-sectional study was conducted in two NHs of south-western France, following the investigation of COVID-19 clusters (February-March 2021). SARS-CoV-2-confirmed infection was defined by positive RT-PCR. Antibodies neutralization capacities were tested in a subgroup of fully-vaccinated and seropositive-residents. RESULTS: Of the 152 residents, 66% were female with median age 87 years (IQR: 80.0-90.2). Overall, 132 (87%) residents received 2 doses of vaccine, 14 (9%) one dose and 6 (4%) were unvaccinated. Forty-seven (31%) residents had confirmed infection (45 (98%) with variant 20I/501Y.V1). All 6 non-vaccinated residents, 4 /14 who had one dose and 37/132 that had two doses, were infected. Of the 39 residents reporting symptoms, 12 and 3 presented severe and critical disease, respectively. One resident with a confirmed infection died. Infected-residents had a median anti-S IgG titre of 19 116.0 (IQR: 3 028.0-39 681.8 AU/mL), 19 times higher than that of non-infected vaccinated persons (1,207.0; IQR: 494.0-2,782.0). In the subgroup of 19 residents tested for neutralizing antibodies, the neutralizing titre (50%) was strongly positively correlated with the anti-S IgG titre (correlation coefficient = 0.83), and 1.5 times higher for the infected than non-infected residents [5.9 (IQR: 5.3-6.9) vs. 3.6 (2.9-3.8)].CONCLUSION: Institutionalized elderly persons who undergo breakthrough infection develop higher titres of anti-S IgGs, which are strongly correlated with the neutralizing capacity of the antibodies. These results advocate for additional vaccine doses in this population.
dc.language.isoENen_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/
dc.subject.enCOVID-19
dc.subject.enVaccine
dc.subject.enNeutralizing antibodies
dc.subject.enSARS-CoV-2
dc.subject.enNursing homes
dc.title.enPost-vaccination SARS-cov-2 infection in nursing home residents, Bordeaux, France
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.jcv.2022.105134en_US
dc.subject.halSciences du Vivant [q-bio]/Médecine humaine et pathologie/Maladies infectieusesen_US
dc.subject.halSciences du Vivant [q-bio]/Médecine humaine et pathologie/Maladies émergentesen_US
dc.subject.halSciences du Vivant [q-bio]/Médecine humaine et pathologie/Gériatrie et gérontologieen_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.subject.halSciences du Vivant [q-bio]/Immunologie/Vaccinologieen_US
bordeaux.journalJournal of Clinical Virologyen_US
bordeaux.page105134en_US
bordeaux.volume149en_US
bordeaux.hal.laboratoriesMFP (Laboratoire Microbiologie Fondamentale et Pathogénicité) - UMR 5234en_US
bordeaux.institutionCNRSen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcehal
hal.identifierhal-03648875
hal.version1
hal.exportfalse
workflow.import.sourcehal
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal%20of%20Clinical%20Virology&rft.date=2022&rft.volume=149&rft.spage=105134&rft.epage=105134&rft.eissn=1386-6532&rft.issn=1386-6532&rft.au=LARTIGAU,%20Marion&OUATTARA,%20Eric&TUMIOTTO,%20Camille&WODRICH,%20Harald&BUSSON,%20Laurent&rft.genre=article


Files in this item

Thumbnail
Name:
BPH_JCV_2022_Lartigau.pdf
Size:
534.9Kb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record